Approval · Notice of Compliance 3320 · 1997
APO-BROMOCRIPTINE: Notice of Compliance 3320
Issued January 8, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3320
- Date
- January 8, 1997
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength and dosage form
- Therapeutic class
- Prolactin inhibitor, growth hormone suppressant in acromegaly, adjunctive medication in parkinson's disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APO-BROMOCRIPTINE | 02230454 | Marketed |
Medicinal ingredients
- BROMOCRIPTINE MESYLATE 5 MG per CAP